Buffett Slams Ozempic Overdose: A 4.5/10 Healthcare Portfolio Roast

Well, hello there. Pull up a chair. I was just looking over this portfolio of yours, and I had to crack open a second Cherry Coke just to make sure my eyes weren't playing tricks on me. You’ve named this the "Global Life Science Innovators" fund, and you certainly weren't kidding.

Charlie Munger—bless his heart—used to say that to get rich, you don't need to know everything about everything, you just need to know a little bit about one thing and stick to your circle of competence. Now, it looks to me like you've decided your circle of competence is entirely populated by doctors, surgeons, and pharmacists. There's a fine line between knowing your circle and putting a blindfold on to the rest of the American economy. We like concentration at Berkshire, but what you’ve built here requires a medical degree just to understand the risks. Let’s take a look under the hood and see if we can’t diagnose what’s going on.

First things first, let's talk about your cash reserves. You are sitting on a mere 3.2% in cash. I've always said that cash is to a business as oxygen is to an individual: never thought about when it is present, the only thing in mind when it is absent. At 3.2%, you are gasping for air. You have absolutely no dry powder for when Mr. Market gets depressed and starts offering up wonderful businesses at bargain prices.

Looking at your sector breakdown, you have a staggering 80.8% of your money tied up in Healthcare. To call this "concentrated" is the understatement of the century. You are heavily betting on North America (82%), which I approve of—never bet against America—but you are doing it almost entirely through the lens of one highly regulated industry.

You’ve got over 53% of your portfolio chasing Growth. Your two biggest individual positions are Eli Lilly at 11.2% and Novo Nordisk at 9.7%. Now, these are wonderful businesses with incredible economics right now, but you are paying an enormous premium for the current weight-loss drug craze. A wonderful company at a fair price is what we look for, but I suspect you’re paying a perfect price for a wonderful company here.

I do appreciate that nearly 50% of your holdings rely on intangible assets like patents and brands, and another 22% have high switching costs. Companies like Intuitive Surgical and Stryker have fantastic competitive moats—once a hospital installs a million-dollar surgical robot and trains its staff, they aren't switching to a competitor anytime soon. UnitedHealth Group (8.5%) is a terrific compounder with a massive scale advantage. But the structural way you've built this house leaves it vulnerable to a single storm.

🚩 The "Ozempic Overdose" Risk

Having over 20% of your money in Eli Lilly and Novo Nordisk means you are chasing a very hot trend. Mr. Market is currently euphoric about GLP-1 drugs. What happens if a cheaper alternative emerges, or if long-term side effects trigger regulatory action? You have no margin of safety built into these valuations.

🚩 Double-Dipping and Paying for the Privilege

You own 13.9% in a broad Healthcare ETF (XLV), while simultaneously holding massive individual positions in UnitedHealth, Eli Lilly, Johnson & Johnson, and Thermo Fisher. All of those companies are the biggest weightings inside that exact same ETF! You are overlapping your investments, concentrating your risk, and paying an ETF expense ratio to hold the exact same stocks you already own outright.

🚩 Patent Cliffs and Stroke-of-the-Pen Risk

With half your portfolio relying on patents as their competitive moat, you are exposed to what Charlie and I call "stroke-of-the-pen" risk. Congress can change Medicare negotiation rules or patent laws overnight. When a patent expires, profits can vanish. That's a structural weakness when 80% of your wealth is in one industry.

🚩 Speculating Outside the Strike Zone

You’ve got almost 6% in speculation, including Moderna and a pre-IPO biotech startup. We don't buy what we don't understand, and trying to guess which pre-revenue biotech firm is going to get FDA approval is a lot like buying lottery tickets. It's speculation, not investing.

I have to give this portfolio a 4.5 out of 10.

You own some truly wonderful businesses—UnitedHealth, Johnson & Johnson, and Medtronic are cash-generating machines. But the portfolio construction is poor. You've confused picking good stocks with building a durable portfolio, and your lack of cash leaves you completely paralyzed if a market correction happens tomorrow.

Here is my prescription for you:

1. Build your cash reserves: Stop buying for a while and let your dividends and new capital build your cash position to at least 10-15%. You need a bucket ready when it rains gold, not a thimble.

2. Cure the overlap: Decide if you want to be an active stock picker or a passive indexer. If you love your individual biotech and pharma picks, sell the XLV ETF and use the capital to buy into entirely different sectors.

3. Broaden your circle of competence: The American economy is a magnificent compounding machine. Look for businesses with durable competitive advantages in other sectors—banks, consumer goods, railroads, or energy—to protect yourself from healthcare-specific regulations.

4. Trim the momentum: Consider taking some profits off the table with your weight-loss drug makers while Mr. Market is still willing to pay a premium.

Remember, diversification is protection against ignorance. It makes little sense if you know what you are doing. But unless you have a crystal ball for the FDA's next ten years of approvals, you are taking on more risk than you realize.

“The stock market is designed to transfer money from the active to the patient.” Take a deep breath, hold some cash, and think in decades, not in drug trials.